Dongyang Li

机构：Jiujiang University, Central University of Finance and Economics, Henan University of Traditional Chinese Medicine, Tianjin Medical University Cancer Institute and Hospital, Hanmi Pharmaceutical (South Korea), Sinocelltech Group (China), Beijing Hospital, Changchun University of Chinese Medicine, First Hospital of China Medical University, First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Central Hospital of Zibo, First Affiliated Hospital of Henan University, China Medical University · ORCID：0000-0002-6317-7853

发表论文 145 篇 · 总被引 1324 次 · h-index 20

代表论文

• Immune-metabolic interactions shape the fibrotic landscape of diabetic kidney disease: emerging mechanisms and therapeutic prospects (2026 · Frontiers in Physiology · 被引 4)
• Macrophage-based therapeutic strategies in glioblastoma: advancements in drug delivery and immunotherapy (2026 · Frontiers in Oncology · 被引 2)
• Population Pharmacokinetics of SCT510 (a Bevacizumab Biosimilar) and Avastin® in Healthy Subjects and Patients with Non-squamous Non-small Cell Lung Cancer (2026 · Clinical Drug Investigation · 被引 2)
• From benchside avatars to bedside breakthroughs: Patient-derived organoids in the new era of cancer immunotherapy (2025 · Translational Oncology · 被引 2)
• Wet dreams: eco-subjectivity, mineral washing, and the cultural politics of electric mobility (2025 · Continuum · 被引 2)
• Mechanistic insights into Shenqi Dihuang decoction in the treatment of immunoglobulin a nephropathy (2026 · Frontiers in Pharmacology · 被引 1)